Whereas tumors regrew after stopping combination therapy, we demonstrated a sustained effect on the tumor microenvironment, including rebalancing tumor cytokines and altered localization of CD8+ T cells, emphasizing roles for C5a during early, benign tumorigenesis. This evidence concerns the gene C5AR1 and neoplasm.